Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Frequently asked questions
What sector does Disc Medicine Inc. (IRON) operate in?
Disc Medicine Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Disc Medicine Inc. (IRON) current stock price?
As of the latest data, Disc Medicine Inc. stock price is $79.90, with a previous close of $77.66. Disc Medicine Inc. gained $2.24 in the last trading session, representing a 2.88% increase.
What is Disc Medicine Inc. (IRON) current market capitalization?
Disc Medicine Inc. market cap is approximately 3.07 billion.
What is Disc Medicine Inc. (IRON) Earnings Per Share (EPS)?
The trailing EPS is -$6.58, and the forward EPS is -$7.08.
What is Disc Medicine Inc. (IRON) EBITDA?
Disc Medicine Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -58.47 million.
Does Disc Medicine Inc. (IRON) pay dividends?
No. Disc Medicine Inc. does not pay a dividend.
When is Disc Medicine Inc. (IRON) next earnings report?
Disc Medicine Inc. is expected to release its next earnings report on September 30, 2026.
What is Disc Medicine Inc. (IRON) beta (volatility) score?
Disc Medicine Inc. has a beta of 2.110, indicating very high volatility compared to the market.
